Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.

Stereotaxis CEO David Fischel says the MAGiC catheter was designed "to overcome the natural limitations of manual pull-wire ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond ...

Dr. Peter Weiss, one of the biggest boosters of robotic magnetic navigation, offers his perspective on the needs of EPs and ...

Stereotaxis has won FDA approval for the MAGiC Magnetic Interventional Ablation Catheter. The device is a robotically ...

FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation can ...

The MAGiC catheter is designed to perform minimally invasive cardiac ablation procedures that treat various forms of ...

Cardiac Electrophysiology Institute Expands Catheter Ablation Access For Los Angeles Heart Rhythm Patients. <a href = target= ...

Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a ...

Research indicates that non-shockable cardiac arrest is associated with higher mortality rates compared to cardiac arrest cases wherein shockable rhythms such as ventricular fibrillation or pulseless ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond ...

Fatal cardiac tamponade is a well recognised complication of the use of central venous catheters in neonatal patients. There is controversy over optimum catheter tip position to balance catheter ...